Compare RVSB & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RVSB | BNTC |
|---|---|---|
| Founded | 1923 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.5M | 315.4M |
| IPO Year | 1997 | 2020 |
| Metric | RVSB | BNTC |
|---|---|---|
| Price | $6.45 | $7.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $23.75 |
| AVG Volume (30 Days) | 44.8K | ★ 154.2K |
| Earning Date | 10-27-2026 | 11-13-2026 |
| Dividend Yield | ★ 1.23% | N/A |
| EPS Growth | N/A | ★ 6.67 |
| EPS | ★ 0.18 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $42.74 | N/A |
| Revenue Next Year | $5.53 | N/A |
| P/E Ratio | $36.11 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.88 | $7.89 |
| 52 Week High | $6.72 | $14.39 |
| Indicator | RVSB | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 59.92 | 37.62 |
| Support Level | $5.23 | N/A |
| Resistance Level | N/A | $13.87 |
| Average True Range (ATR) | 0.18 | 0.66 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 56.06 | 5.18 |
Riverview Bancorp Inc is the bank holding company. The Company's operations are managed along two operating segments, consisting of banking operations performed by the Bank and trust and investment services performed by the Trust Company. The Bank is engaged mainly in the business of attracting deposits from the general public and using such funds, together with other borrowings, to make various commercial business, commercial real estate, land, multi-family real estate, real estate construction and consumer loans. Additionally, the Trust Company offers trust and investment. Its operations into two operating segments, consisting of banking operations and trust and investment services, these operating segments are aggregated into a single reportable operating segment.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.